Mural Oncology finalizes share price for upcoming acquisition by XOMA Royalty, with cash consideration determined at $2.035 per share.
Quiver AI Summary
Mural Oncology plc announced the final determination of the Additional Price Per Share in its acquisition deal with XOMA Royalty Corporation and XRA 5 Corp, set at $0.000, resulting in a total cash consideration of $2.035 per share for Mural shareholders upon closing. This acquisition, structured under an Irish High Court sanctioned scheme, is expected to finalize in early December 2025, pending satisfaction of remaining conditions and court approval. The announcement includes cautionary notes on forward-looking statements and compliance with the Irish Takeover Rules regarding disclosures of significant interest in Mural's securities, while also reminding that distribution of the release may be restricted in certain jurisdictions.
Potential Positives
- The determination of the Additional Price Per Share as $0.000 and the total cash consideration of $2.035 per share indicates a clear financial outcome for Mural shareholders, providing them with a definitive return on their investment.
- The upcoming acquisition by XOMA Royalty, expected to close in early December 2025, signals a strategic partnership that may enhance Mural's market position.
- The acquisition process being sanctioned by the Irish High Court ensures that the transaction is being conducted in compliance with relevant legal frameworks, which adds a layer of credibility to the process.
Potential Negatives
- The determination of the Additional Price Per Share as $0.000 raises concerns regarding shareholder value and indicates a possible lack of financial stability for Mural Oncology.
- The press release indicates that the acquisition is contingent upon several closing conditions, including the sanction of the Scheme by the Irish High Court, which introduces uncertainty around the completion of the transaction.
- The warning regarding forward-looking statements underscores the risks associated with the Acquisition, suggesting that the expected benefits may not be realized and increasing perceived volatility for investors.
FAQ
What is the acquisition deal between Mural Oncology and XOMA Royalty?
The acquisition involves XOMA Royalty's subsidiary, Sub, acquiring Mural's entire issued share capital under an Irish High Court sanctioned scheme.
What is the cash consideration per share for Mural shareholders?
Mural shareholders will receive $2.035 in cash per share upon closing of the Acquisition.
When is the expected closing date for the Acquisition?
The Acquisition is expected to close in early December 2025, pending satisfaction of closing conditions.
What forward-looking statements are included in the announcement?
The announcement includes statements related to the intention to complete the Acquisition and anticipated timing, with certain risks disclosed.
Where can I find more information about the transaction?
More details are available on Mural's website at https://ir.muraloncology.com/ following the announcement's publication.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MURA Insider Trading Activity
$MURA insiders have traded $MURA stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $MURA stock by insiders over the last 6 months:
- CAROLINE LOEW (Chief Executive Officer) sold 12,531 shares for an estimated $30,475
- ADAM D. CUTLER (Chief Financial Officer) sold 7,148 shares for an estimated $14,939
- MAIKEN KESON-BROOKES (See Remarks) has made 0 purchases and 2 sales selling 4,730 shares for an estimated $11,730.
- VICKI L GOODMAN (Chief Medical Officer) sold 5,036 shares for an estimated $10,474
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MURA Hedge Fund Activity
We have seen 26 institutional investors add shares of $MURA stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 1,722,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,253,340
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,323,877 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,740,425
- PROSIGHT MANAGEMENT, LP removed 900,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,862,999
- SOLAS CAPITAL MANAGEMENT, LLC removed 887,995 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,193,347
- ACORN CAPITAL ADVISORS, LLC removed 653,779 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,353,322
- OMERS ADMINISTRATION CORP added 511,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,057,770
- LMR PARTNERS LLP removed 500,000 shares (-96.8%) from their portfolio in Q3 2025, for an estimated $1,034,999
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“ Mural ”) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) (“ XOMA Royalty ”), XRA 5 Corp. (“ Sub ”) and Mural announced on August 20, 2025 (the “ Transaction Agreement ”), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction Agreement as $0.000. As a result, the total cash consideration payable to Mural shareholders on closing of the Acquisition (as defined below) will be $2.035 in cash per share.
As previously announced on August 20, 2025, XOMA Royalty, Sub and Mural entered into the Transaction Agreement pursuant to which Sub, a wholly-owned subsidiary of XOMA Royalty, has agreed to acquire the entire issued and to be issued share capital of Mural (the “ Acquisition ”) pursuant to an Irish High Court sanctioned “scheme of arrangement” under Chapter 1 of Part 9 of the Irish Companies Act of 2014 (the “ Scheme ”).
The Acquisition is expected to close in early December 2025, subject to the satisfaction of the outstanding closing conditions and the sanction of the Scheme by the Irish High Court.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION
FOR IMMEDIATE RELEASE
Enquiries
Mural Oncology plc
[email protected]
Lucid Capital Markets, LLC (Financial Adviser to Mural)
570 Lexington Ave, 40th Floor
New York, NY 10022
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this announcement regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Mural, XOMA Royalty or Sub. Forward-looking statements are intended to be identified by words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “plan”, “believe”, “will”, “may”, “would”, “could” or “should” or other words of similar meaning or the negative thereof. Forward-looking statements include but are not limited to statements regarding Mural, XOMA Royalty and Sub’s intention to consummate the Acquisition and the expected timing of the closing of the Acquisition.
These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements. Risks and uncertainties that may cause actual results to differ from expectations include: uncertainties as to the possibility that closing conditions for the Acquisition may not be satisfied or waived, including the failure to receive sanction of the Scheme by the Irish High Court; the other risks and uncertainties pertaining to Mural’s business, including those described in Mural’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) and the definitive proxy statement filed with the SEC on September 23, 2025, as well as Mural’s subsequent filings with the SEC; and other potential risks and uncertainties related to XOMA Royalty, including those described in more detail in XOMA Royalty’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and its other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All subsequent oral or written forward-looking statements attributable to Mural, XOMA Royalty or Sub or any persons acting on their behalf are expressly qualified in their entirety by the cautionary statement above. None of Mural, XOMA Royalty or Sub undertake any obligation to update or revise the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.
Statement Required by the Irish Takeover Rules
The directors of Mural accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Mural (who have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.
Disclosure Requirements of the Irish Takeover Rules
Under Rule 8.3(b) of the Irish Takeover Rules, any person who is, or becomes, “interested” (directly or indirectly) in 1% or more of any class of “relevant securities” of Mural must disclose all “dealings” in such “relevant securities” during the “offer period”. The disclosure of a “dealing” in “relevant securities” by a person to whom Rule 8.3(b) applies must be made by no later than 3:30pm (U.S. Eastern Time) on the “business day” following the date of the relevant “dealing”. A dealing disclosure must contain the details specified in Rule 8.6(b) of the Irish Takeover Rules, including details of the dealing concerned and of the person’s interests and short positions in any “relevant securities” of Mural.
All “dealings” in “relevant securities” of Mural by a bidder, or by any party acting in concert with a bidder, must also be disclosed by no later than 12:00 noon (U.S. Eastern Time) on the “business day” following the date of the relevant “dealing”.
If two or more persons co-operate on the basis of an agreement, either express or tacit, either oral or written, to acquire an “interest” in “relevant securities” of Mural, they will be deemed to be a single person for the purpose of Rule 8.3(a) and (b) of the Irish Takeover Rules.
A disclosure table, giving details of the companies in whose “relevant securities” dealing disclosures should be made, can be found on the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie .
“Interests in securities” arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an “interest” by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.
Terms in quotation marks in this section are defined in the Irish Takeover Rules, which can also be found on the Irish Takeover Panel’s website.
If you are in any doubt as to whether or not you are required to disclose a “dealing” under Rule 8, please consult the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020.
General
The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this announcement and all other documents relating to the Acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such restricted jurisdictions. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, each of Mural, XOMA Royalty and Sub disclaims any responsibility or liability for the violations of any such restrictions by any person.
Publication on a Website
In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this announcement will be available on Mural’s website at https://ir.muraloncology.com/ by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication of this announcement. Neither the content of the website referred to in this announcement nor the content of any other websites accessible from hyperlinks on such website is incorporated into, or forms part of, this announcement.